AIM: To evaluate the tumor repositioning during gated volumetric modulated arc therapy (VMAT) for liver stereotactic body radiotherapy(SBRT) treatment using implanted fiducial markers and intrafraction kilovoltage (kV) images acquired during dose delivery. MATERIALS AND METHODS: Since 2012, 47 liver cancer patients with implanted fiducial markers were treated using the gated VMAT technique with a Varian Truebeam STx linear accelerator. The fiducial markers were implanted inside or close to the tumor target before treatment simulation. They were defined at the maximum inhalation and exhalation phases on a 4-dimensionnal computed tomography (4DCT) acquisition. During the treatment, kV images were acquired just before the beam-on at each breathing cycle at maximum exhalation and inhalation phases to verify the fiducial markers positions. For the five first fractions of treatment in the first ten consecutive patients, a total of 2705 intrafraction kV images were retrospectively analyzed to assess the differences between expected and actual positions of the fiducial markers along the cranio-caudal (CC) direction during the exhalation phase. RESULTS: The mean absolute intrafractional fiducial marker deviation along the CC direction was 1.0 mm at the maximum exhalation phase. In 99%, 95% and 90% cases, the fiducial marker deviations were ≤4.5 mm, 2.8 mm and 2.2 mm, respectively. CONCLUSION: Intrafraction kV images allowed us to ensure the consistency of tumor repositioning during treatment. In 99% cases, the fiducial marker deviations were ≤4.5 mm corresponding to our 5 mm treatment margin. This margin seems to be well-adapted to the gated VMAT SBRT treatment in liver disease.
AIM: To evaluate the tumor repositioning during gated volumetric modulated arc therapy (VMAT) for liver stereotactic body radiotherapy(SBRT) treatment using implanted fiducial markers and intrafraction kilovoltage (kV) images acquired during dose delivery. MATERIALS AND METHODS: Since 2012, 47 liver cancerpatients with implanted fiducial markers were treated using the gated VMAT technique with a Varian Truebeam STx linear accelerator. The fiducial markers were implanted inside or close to the tumor target before treatment simulation. They were defined at the maximum inhalation and exhalation phases on a 4-dimensionnal computed tomography (4DCT) acquisition. During the treatment, kV images were acquired just before the beam-on at each breathing cycle at maximum exhalation and inhalation phases to verify the fiducial markers positions. For the five first fractions of treatment in the first ten consecutive patients, a total of 2705 intrafraction kV images were retrospectively analyzed to assess the differences between expected and actual positions of the fiducial markers along the cranio-caudal (CC) direction during the exhalation phase. RESULTS: The mean absolute intrafractional fiducial marker deviation along the CC direction was 1.0 mm at the maximum exhalation phase. In 99%, 95% and 90% cases, the fiducial marker deviations were ≤4.5 mm, 2.8 mm and 2.2 mm, respectively. CONCLUSION: Intrafraction kV images allowed us to ensure the consistency of tumor repositioning during treatment. In 99% cases, the fiducial marker deviations were ≤4.5 mm corresponding to our 5 mm treatment margin. This margin seems to be well-adapted to the gated VMAT SBRT treatment in liver disease.
Authors: Oleg N Vassiliev; Uwe Titt; Falk Pönisch; Stephen F Kry; Radhe Mohan; Michael T Gillin Journal: Phys Med Biol Date: 2006-03-21 Impact factor: 3.609
Authors: Paul J Keall; Gig S Mageras; James M Balter; Richard S Emery; Kenneth M Forster; Steve B Jiang; Jeffrey M Kapatoes; Daniel A Low; Martin J Murphy; Brad R Murray; Chester R Ramsey; Marcel B Van Herk; S Sastry Vedam; John W Wong; Ellen Yorke Journal: Med Phys Date: 2006-10 Impact factor: 4.071
Authors: A Sam Beddar; Kristofer Kainz; Tina Marie Briere; Yoshikazu Tsunashima; Tinsu Pan; Karl Prado; Radhe Mohan; Michael Gillin; Sunil Krishnan Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-01 Impact factor: 7.038
Authors: Per Rugaard Poulsen; Esben S Worm; Jørgen B B Petersen; Cai Grau; Walther Fledelius; Morten Høyer Journal: Radiother Oncol Date: 2014-07-02 Impact factor: 6.280
Authors: Wouter Wunderink; Alejandra Méndez Romero; Willy de Kruijf; Hans de Boer; Peter Levendag; Ben Heijmen Journal: Int J Radiat Oncol Biol Phys Date: 2008-07-01 Impact factor: 7.038
Authors: Anna Kirilova; Gina Lockwood; Perry Choi; Neelufer Bana; Masoom A Haider; Kristy K Brock; Cynthia Eccles; Laura A Dawson Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-06 Impact factor: 7.038